HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment
The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.
Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.
They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site. This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.
Although current treatments cannot cure Parkinson's disease completely, stem cell therapy a promising potential treatment. It involves cultivating stem cells for differentiation into new and healthy cells, tissues or organs which can then be transplanted to human body to replace damaged or dead cells.
Conventional stem cell culturing techniques require a large number of additional growth factors in a culture medium. The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body. Furthermore, the brain‐like structures obtained from this method usually poorly resemble their counterparts in the brain. Efficiency of the conventional culturing techniques is low as the process spans more than a month, resulting in a high risk of contamination.
The pioneering nanomatrix, developed by a research team led by Professor Ken Yung Kin-lam, Professor of the Department of Biology and Dr Jeffery Huang Zhifeng, Associate Professor of the Department of Physics at HKBU, can induce the rapid and specific differentiation of neural stem cells into miniature substantia nigra-like structures (mini-SNLSs). These mini-SNLSs mainly comprise dopaminergic neurons and they can replace the damaged or degenerated cells in the substantia nigra in the brain.
The nanomatrix consists of a silica plate coated with a nanostructure layer. Thickness of the nanomatrix is only 550–730 nm, yet there are trillions of nanozigzag structures on the surface which can initiate the growth of neural stem cells into mini-SNLSs without the use of chemical growth factors.
"When the neural stem cells come into physical contact with our tailor-made nanozigzag matrix in vitro, the 'physical massage' can induce the cells to differentiate rapidly into the desired dopaminergic neurons. A self-organised mini-brain-like structure can be developed in only 2 weeks with risk of carcinogenesis substantially reduced," said Dr Huang.
According to Professor Yung, the technology "lays the foundation for research into stem cell therapies that may ultimately cure Parkinson's disease." He also believes the invention has shown great potential for the treatment of other incurable diseases, such as Alzheimer's disease and certain types of cancer.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance